结直肠癌的分子预后因素:5年随访。

IF 1.2 4区 医学 Q4 DEVELOPMENTAL BIOLOGY
Alina Elena Ciobanu, Daniel Cristian Pîrvu, Cristina Maria Mărginean, Anda Lorena Dijmărescu, Adriana Estefa Muñoz-Groza, Cristian Meşină, Tudor Adrian Bălşeanu, Vlad Dumitru Băleanu, Tiberiu Ştefăniţă Ţenea-Cojan, Daniela Ciobanu
{"title":"结直肠癌的分子预后因素:5年随访。","authors":"Alina Elena Ciobanu,&nbsp;Daniel Cristian Pîrvu,&nbsp;Cristina Maria Mărginean,&nbsp;Anda Lorena Dijmărescu,&nbsp;Adriana Estefa Muñoz-Groza,&nbsp;Cristian Meşină,&nbsp;Tudor Adrian Bălşeanu,&nbsp;Vlad Dumitru Băleanu,&nbsp;Tiberiu Ştefăniţă Ţenea-Cojan,&nbsp;Daniela Ciobanu","doi":"10.47162/RJME.64.1.08","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.</p>","PeriodicalId":54447,"journal":{"name":"Romanian Journal of Morphology and Embryology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/e3/RJME-64-1-65.PMC10257784.pdf","citationCount":"1","resultStr":"{\"title\":\"Molecular prognostic factors in colorectal cancer: 5-year follow-up.\",\"authors\":\"Alina Elena Ciobanu,&nbsp;Daniel Cristian Pîrvu,&nbsp;Cristina Maria Mărginean,&nbsp;Anda Lorena Dijmărescu,&nbsp;Adriana Estefa Muñoz-Groza,&nbsp;Cristian Meşină,&nbsp;Tudor Adrian Bălşeanu,&nbsp;Vlad Dumitru Băleanu,&nbsp;Tiberiu Ştefăniţă Ţenea-Cojan,&nbsp;Daniela Ciobanu\",\"doi\":\"10.47162/RJME.64.1.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.</p>\",\"PeriodicalId\":54447,\"journal\":{\"name\":\"Romanian Journal of Morphology and Embryology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/e3/RJME-64-1-65.PMC10257784.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Romanian Journal of Morphology and Embryology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.47162/RJME.64.1.08\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DEVELOPMENTAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian Journal of Morphology and Embryology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47162/RJME.64.1.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

结直肠癌(CRC)是一种常见病和致死性疾病。发生结直肠癌的风险是由环境和遗传因素决定的。手术治疗是晚期结直肠癌患者的主要治疗方式。近年来,在对肿瘤进行基因分析后,用作靶向治疗的生物制剂得到了特殊的重视:贝伐单抗(Avastin)、西妥昔单抗(Erbitux)、zivaflibercept (Zaltrap)。我们报告了一项基于罗马尼亚克拉约瓦急诊县临床医院外科手术的结直肠癌患者的46例结直肠肿瘤切除标本的研究。组织病理学检查和组织切片免疫组化染色确定侵袭程度。使用Kaplan-Meier检验,我们计算了生存时间与免疫组织化学预后因素之间的相关系数。术后随访60个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Molecular prognostic factors in colorectal cancer: 5-year follow-up.

Molecular prognostic factors in colorectal cancer: 5-year follow-up.

Molecular prognostic factors in colorectal cancer: 5-year follow-up.

Molecular prognostic factors in colorectal cancer: 5-year follow-up.

Colorectal cancer (CRC) is a frequently diagnosed and lethal disease. The risk of developing CRC is determined by environmental and genetic factors. Surgical treatment is the main curative modality for patients with CRC up to stage III. In recent years, a special place has been given to biological agents used as targeted therapy following the genetic analysis of the tumor: Bevacizumab (Avastin), Cetuximab (Erbitux), Ziv-aflibercept (Zaltrap). We present a study based on 46 colorectal tumor resection specimens from patients operated for CRC in the Surgery Departments of the Emergency County Clinical Hospital of Craiova, Romania. Histopathological examination and immunohistochemistry staining of tissue sections were performed to determine the degree of aggressiveness. Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
20.00%
发文量
221
审稿时长
3-8 weeks
期刊介绍: Romanian Journal of Morphology and Embryology (Rom J Morphol Embryol) publishes studies on all aspects of normal morphology and human comparative and experimental pathology. The Journal accepts only researches that utilize modern investigation methods (studies of anatomy, pathology, cytopathology, immunohistochemistry, histochemistry, immunology, morphometry, molecular and cellular biology, electronic microscopy, etc.).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信